Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07494032 · ClinicalTrials.gov registry record · NA
Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty
A NA study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT07494032 is a NA study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 350 participants.
The verdict
NCT07494032, a NA study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
This study is a prospective double-blind randomized controlled trial to evaluate the effect of extended oral TXA after primary total TKA on short-term and mid-term postoperative outcomes, including function, pain, and postoperative complications over a 24-month period, with evaluations at 6 weeks, 3 months, 12 months, and 24 months. Each group of 175 patients will receive either extended oral TXA 1.95g daily or placebo for 7 days postoperatively. Function will be assessed by Knee Injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR) scores measured at all post operative time points as well as range of motion (ROM) (measured at all visits).
Interventions
- DRUG Placebo
- DRUG Tranexamic acid (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2029-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07494032
The ClinicalTrials.gov registry entry for NCT07494032 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07494032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07494032 about?
NCT07494032 is a clinical study titled "Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty". This study is a prospective double-blind randomized controlled trial to evaluate the effect of extended oral TXA after primary total TKA on short-term and mid-term postoperative outcomes, including function, pain, and postoperative complications over a 24-month period, with evaluations at 6 weeks, 3...
What is the current status of trial NCT07494032?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2026-05-01. Estimated completion is 2029-05-01.
What interventions are being tested in trial NCT07494032?
The interventions under investigation include: Placebo (DRUG), Tranexamic acid (TXA) (DRUG).
Who is sponsoring clinical trial NCT07494032?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.